Biogen's New Alzheimer's Drug Could Cost Medicare Billions of Dollars a Year, Report Finds

·3 min read

Biogen's New Alzheimer's Drug Could Cost Medicare Billions of Dollars a Year, Report Finds originally appeared on NBC Sports Philadelphia

  • Biogen’s new Alzheimer’s drug, Aduhelm, could cost Medicare billions of dollars a year, according to an analysis by the nonprofit Kaiser Family Foundation.

  • Biogen said it is charging $56,000 for an annual course of the new treatment, which was approved by the FDA on Monday.

  • “If 1 million Medicare beneficiaries receive Aduhelm, which may even be on the low end of Biogen’s expectations, spending on Aduhelm alone would exceed $57 billion” a year, the group said, “far surpassing spending on all other Part B-covered drugs combined.”